Journal of Oncology

Immunotherapy: A New Hope for Cancer Patients

Publishing date
01 Oct 2019
Submission deadline
17 May 2019

Lead Editor

1King George's Medical University, Lucknow, India

2Banaras Hindu University, Varanasi, India

3University of Sheffield, Sheffield, UK

4University of Nebraska Medical Center, Omaha, USA

5CSIR-Indian Institute of Toxicology Research, Lucknow, India

Immunotherapy: A New Hope for Cancer Patients


In December 1971, the President of the United States of America established an extended effort to find a cure for cancer. Since then, the cancer research community has built a significant advance in understanding the pathogenesis of the disease. However, cancer remains one of the leading causes of death worldwide. Chemotherapy, radiation, and surgery have been utilized as the primary weapon against cancer. All the same, these treatments have added little to the overall survival of the patients. In addition, these therapies produce numerous side effects and cannot be afforded by a wide range of people.

Cancer immunotherapy was selected as the breakthrough therapy of 2013 in the field of cancer treatment (Jennifer Couzin-Frankel, Science, 342 (2013): 1432-1433; Marcia McNutt, Science 342 (2013): 1417). Immunotherapy aims to target the immune system and not the tumor itself. The immune responses have the potential to increase and sustain over time. It undergoes pseudoprogression which may reflect the development of antitumor immunity. Immunotherapy uses antibodies that bind to and inhibit the function of cancer related proteins in a specific manner. Immunotherapy also includes usage of vaccines and T cell infusions.

Although immunotherapy has provided a new hope, it does not help every cancer patient. Why some patients do not benefit from immunotherapy is the focus of this special issue. We invite the authors to contribute original research articles as well as review articles to this special issue. We are particularly interested in articles that offer an overview of the existing concepts, novel findings, controversies, and challenges in this area. Articles on future prospects of immunotherapy are invited.

Potential topics include but are not limited to the following:

  • Multidrug resistance and cancer immunotherapy
  • Immune system and multiple steps of tumor growth
  • Immunological aspects of epithelial-to-mesenchymal transition
  • Cancer stem cells as target for immunotherapy
  • Role of inflammatory molecules in cancer immunotherapy
  • Role of noncoding RNAs in cancer immunotherapy
  • Immuno-oncology signaling molecules
  • Role of tumor microenvironment in cancer immunotherapy
  • Role of metabolism in cancer immunotherapy
  • Role of human microbiome in cancer immunotherapy
  • Safety and toxicity associated with cancer immunotherapy


  • Special Issue
  • - Volume 2019
  • - Article ID 5269062
  • - Review Article

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors

Anne Rogiers | Annelies Boekhout | ... | Bart Neyns
  • Special Issue
  • - Volume 2019
  • - Article ID 2186494
  • - Review Article

Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

Rachel E. Cooke | Rachel Koldej | David Ritchie
  • Special Issue
  • - Volume 2019
  • - Article ID 7309205
  • - Review Article

Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma

Fady Ghali | Sunil H. Patel | Ithaar H. Derweesh
  • Special Issue
  • - Volume 2019
  • - Article ID 6072863
  • - Review Article

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma

Chiara Fiorentini | Salvatore Grisanti | ... | Sandra Sigala
  • Special Issue
  • - Volume 2019
  • - Article ID 3406972
  • - Research Article

Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis

Di Wu | Tiejun Chen | ... | Fenfang Wu
  • Special Issue
  • - Volume 2019
  • - Article ID 4508794
  • - Review Article

Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates

Manpreet Sambi | Leila Bagheri | Myron R. Szewczuk
  • Special Issue
  • - Volume 2019
  • - Article ID 3958908
  • - Research Article

PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications

Pramod Darvin | Varun Sasidharan Nair | Eyad Elkord
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
Journal Citation Indicator0.680
Impact Factor4.375

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.